A Feasibility Study of Adjuvant Chemotherapy With Oral Fluoropyrimidine S-1 for Non-small Cell Lung Cancer
Chemotherapy comprised eight courses (4-week administration, 2-week withdrawal) of S-1 (FT,
gineracil, oteracil potassium; Taiho Pharmaceutical, Tokyo, Japan) at 80-120 mg/body/day
according to body surface area (BSA): BSA <1.25 m2, 80 mg/day; BSA >1.25 m2 but <1.5 m2, 100
mg/day; and BSA >1.5 m2, 120 mg/day. S-1 was administered orally, twice daily after meals,
starting within 4 weeks after surgery.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Takeshi Nagayasu, MD. PhD.
Division of Surgical Oncology, Department of Translational Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences
Japan: Institutional Review Board